Upregulation of a small vault RNA (svtRNA2-1a) is an early event in parkinson disease and induces neuronal dysfunction

RNA Biology

Volumn 10, Issue 7, 2013, Pages 1093-1106

  Minones Moyano, Elena ^a,b,c   Friedländer, Marc R ^a,b   Pallares, Joan ^a,b   Kagerbauer, Birgit ^a,b   Porta, Silvia ^c   Escaramis, Georgia ^a,b   Ferrer, Isidre ^c,d   Estivill, Xavier ^a,b   Marti, Eulalia ^a,b  

^a CENTRE FOR GENOMIC REGULATION CRG   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Lincrnas; Microarrays; Neuronal dysfunction; Parkinson disease; SncRNA; Vault RNA

Indexed keywords

DICER; ENDONUCLEASE; RNA; SMALL UNTRANSLATED RNA; SVTRNA2 1A; UNCLASSIFIED DRUG;

ARTICLE; BIOGENESIS; CELL SPECIFICITY; CELL TYPE; CONTROLLED STUDY; DEREGULATION; DOWN REGULATION; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; GENETIC CODE; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; NERVOUS SYSTEM DEVELOPMENT; PARKINSON DISEASE; PRECURSOR; UPREGULATION;

LINCRNAS; MICROARRAYS; NEURONAL DYSFUNCTION; PARKINSON DISEASE; SNCRNA;

ARGONAUTE PROTEINS; BASE SEQUENCE; BRAIN; CELL DIFFERENTIATION; CELL LINE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMANS; MOLECULAR SEQUENCE DATA; NEURONS; NUCLEIC ACID CONFORMATION; OPEN READING FRAMES; PARKINSON DISEASE; REPRODUCIBILITY OF RESULTS; RIBONUCLEASE III; RNA, SMALL UNTRANSLATED; SEQUENCE ALIGNMENT; TRANSCRIPTOME; UP-REGULATION;

EID: 84880898110     PISSN: 15476286     EISSN: 15558584     Source Type: Journal    
DOI: 10.4161/rna.24813     Document Type: Article

References (72)

1. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318:121-34; PMID:15338272.
2. Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 2010; 67:715-25; PMID:20517933; http://dx.doi.org/10.1002/ana.21995.
3. Shulman JM, De Jager PL, Feany MB. Parkinson's disease: genetics and pathogenesis. Annu Rev Pathol 2011; 6:193-222; PMID:21034221; http://dx.doi.org/10.1146/annurev-pathol-011110-130242.
4. Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, Bezard E, et al. Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol 2009; 8:1128-39; PMID:19909911; http://dx.doi.org/10.1016/S1474-4422(09)70293-5.
5. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24:197-211; PMID:12498954.
6. Douglas MR, Lewthwaite AJ, Nicholl DJ. Genetics of Parkinson's disease and parkinsonism. Expert Rev Neurother 2007; 7:657-66; PMID:17563249.
7. Tan EK, Skipper LM. Pathogenic mutations in Parkinson disease. Hum Mutat 2007; 28:641-53; PMID:17385668.
8. Xiromerisiou G, Dardiotis E, Tsimourtou V, Kountra PM, Paterakis KN, Kapsalaki EZ, et al. Genetic basis of Parkinson disease. Neurosurg Focus 2010; 28:E7; PMID:20043722; http://dx.doi.org/10.3171/2009.10.FOCUS09220.
9. Eriksen JL, Przedborski S, Petrucelli L. Gene dosage and pathogenesis of Parkinson's disease. Trends Mol Med 2005; 11:91-6; PMID:15760766.
10. Grunblatt E, Mandel S, Jacob-Hirsch J, Zeligson S, Amariglo N, Rechavi G, et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm 2004; 111:1543-73; PMID:15455214.
11. Mandel S, Grunblatt E, Riederer P, Amariglio N, Jacob-Hirsch J, Rechavi G, et al. Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitinproteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann N Y Acad Sci 2005; 1053:356-75; PMID:16179542.
12. Simunovic F, Yi M, Wang Y, Macey L, Brown LT, Krichevsky AM, et al. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. Brain 2009; 132:1795-809; PMID:19052140; http://dx.doi.org/10.1093/brain/awn323.
13. Zhang Y, James M, Middleton FA, Davis RL. Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms. Am J Med Genet B Neuropsychiatr Genet 2005; 137B:5-16; PMID:15965975.
14. Bueler H. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease. Exp Neurol 2009; 218:235-46; PMID:19303005; http://dx.doi.org/10.1016/j.expneurol.2009.03.006.
15. Cohen G. Oxidative stress, mitochondrial respiration, and Parkinson's disease. Ann NY Acad Sci 2000; 899:112-20; PMID:10863533.
16. Navarro A, Boveris A, Bandez MJ, Sanchez-Pino MJ, Gomez C, Muntane G, et al. Human brain cortex: mitochondrial oxidative damage and adaptive response in Parkinson disease and in dementia with Lewy bodies. Free Radic Biol Med 2009; 46:1574-80; PMID:19298851; http://dx.doi.org/10.1016/j.freeradbiomed.2009.03. 007.
17. Kim J, Inoue K, Ishii J, Vanti WB, Voronov SV, Murchison E, et al. A MicroRNA feedback circuit in midbrain dopamine neurons. Science 2007; 317:1220-4; PMID:17761882.
18. Wang G, van der Walt JM, Mayhew G, Li YJ, Zuchner S, Scott WK, et al. Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am J Hum Genet 2008; 82:283-9.
19. Junn E, Lee KW, Jeong BS, Chan TW, Im JY, Mouradian MM. Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc Natl Acad Sci USA 2009; 106:13052-7; PMID:19628698; http://dx.doi.org/10.1073/pnas.0906277106.
20. Minones-Moyano E, Porta S, Escaramis G, Rabionet R, Iraola S, Kagerbauer B, et al. MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum Mol Genet 2011; 20:3067-78; PMID:21558425; http://dx.doi.org/10.1093/hmg/ddr210.
21. Persson H, Kvist A, Vallon-Christersson J, Medstrand P, Borg A, Rovira C. The non-coding RNA of the multidrug resistance-linked vault particle encodes multiple regulatory small RNAs. Nat Cell Biol 2009; 11:1268-71; PMID:19749744; http://dx.doi.org/10.1038/ncb1972.
22. Jellinger KA. Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm 2004; 111:1219-35; PMID:15480835.
23. Saito Y, Ruberu NN, Sawabe M, Arai T, Kazama H, Hosoi T, et al. Lewy body-related alpha-synucleinopathy in aging. J Neuropathol Exp Neurol 2004; 63:742-9; PMID:15290899.
24. Friedlander MR, Mackowiak SD, Li N, Chen W, Rajewsky N. miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades. Nucleic Acids Res 2012; 40:37-52; PMID:21911355; http://dx.doi.org/10. 1093/nar/gkr688.
25. Burroughs AM, Ando Y, de Hoon MJ, Tomaru Y, Suzuki H, Hayashizaki Y, et al. Deep-sequencing of human Argonaute-Associated small RNAs provides insight into miRNA sorting and reveals Argonaute association with RNA fragments of diverse origin. RNA Biol 2011; 8:158-77; PMID:21911355; http://dx.doi.org/10. 1093/nar/gkr688.
26. Dweep H, Sticht C, Pandey P, Gretz N. miRWalk-Database: Prediction of possible miRNA binding sites by "walking" the genes of three genomes. J Biomed Inform 2011; PMID:21605702; http://dx.doi.org/10.1016/j.jbi.2011.05. 002.
27. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E. The role of site accessibility in microRNA target recognition. Nat Genet 2007; 39:1278-84; PMID:17893677.
28. Sutherland GT, Matigian NA, Chalk AM, Anderson MJ, Silburn PA, Mackay-Sim A, et al. A cross-study transcriptional analysis of Parkinson's disease. PLoS One 2009; 4:e4955; PMID:19305504; http://dx.doi.org/10.1371/journal.pone. 0004955.
29. Taccioli C, Tegner J, Maselli V, Gomez-Cabrero D, Altobelli G, Emmett W, et al. ParkDB: A Parkinson's disease gene expression database. Database (Oxford) 2011; 2011:bar007; PMID:21593080; http://dx.doi.org/10.1093/database/bar007.
30. Somel M, Guo S, Fu N, Yan Z, Hu HY, Xu Y, et al. MicroRNA, mRNA, and protein expression link development and aging in human and macaque brain. Genome Res 2010; 20:1207-18; PMID:20647238; http://dx.doi.org/10.1101/gr.106849.110.
31. Vistica DT, Skehan P, Scudiero D, Monks A, Pittman A, Boyd MR. Tetrazolium-based assays for cellular viability: A critical examination of selected parameters affecting formazan production. Cancer Res 1991; 51:2515-20; PMID:2021931.
32. Berridge MV, Horsfield JA, Tan AS. Evidence that cell survival is controlled by interleukin-3 independently of cell proliferation. J Cell Physiol 1995; 163:466-76; PMID:7775590.
33. Enciu AM, Popescu BO, Gheorghisan-Galateanu A. MicroRNAs in brain development and degeneration. Mol Biol Rep 2011; PMID:21643950; http://dx.doi.org/10.1007/s11033-011-0973-1
34. Hebert SS, Horre K, Nicolai L, Bergmans B, Papadopoulou AS, Delacourte A, et al. MicroRNA regulation of Alzheimer's Amyloid precursor protein expression. Neurobiol Dis 2009; 33:422-8; PMID:19110058; http://dx.doi.org/10.1016/j.nbd. 2008.11.009.
35. Hebert SS, Horre K, Nicolai L, Papadopoulou AS, Mandemakers W, Silahtaroglu AN, et al. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci USA 2008; 105:6415-20; PMID:18434550; http://dx.doi.org/10. 1073/pnas.0710263105.
36. Johnson R, Buckley NJ. Gene dysregulation in Huntington's disease: REST, microRNAs and beyond. Neuromolecular Med 2009; 11:183-99; PMID:19458943; http://dx.doi.org/10.1007/s12017-009-8063-4.
37. Li YY, Cui JG, Hill JM, Bhattacharjee S, Zhao Y, Lukiw WJ. Increased expression of miRNA-146a in Alzheimer's disease transgenic mouse models. Neurosci Lett 2011; 487:94-8; PMID:20934487; http://dx.doi.org/10.1016/j.neulet. 2010.09.079.
38. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007; 129:1401-14; PMID:17604727.
39. Yang JS, Maurin T, Robine N, Rasmussen KD, Jeffrey KL, Chandwani R, et al. Conserved vertebrate mir-451 provides a platform for Dicer-independent, Ago2-mediated microRNA biogenesis. Proc Natl Acad Sci USA 2010; 107:15163-8; PMID:20699384; http://dx.doi.org/10.1073/pnas.1006432107.
40. Nandy C, Mrazek J, Stoiber H, Grasser FA, Huttenhofer A, Polacek N. Epstein-barr virus-induced expression of a novel human vault RNA. J Mol Biol 2009; 388:776-84; PMID:19298825; http://dx.doi.org/10.1016/j.jmb.2009.03.031.
41. Stadler PF, Chen JJ, Hackermuller J, Hoffmann S, Horn F, Khaitovich P, et al. Evolution of vault RNAs. Mol Biol Evol 2009; 26:1975-91; PMID:19491402; http://dx.doi.org/10.1093/molbev/msp112.
42. Berger W, Steiner E, Grusch M, Elbling L, Micksche M. Vaults and the major vault protein: novel roles in signal pathway regulation and immunity. Cell Mol Life Sci 2009; 66:43-61; PMID:18759128; http://dx.doi.org/10.1007/s00018- 008-8364-z.
43. van Zon A, Mossink MH, Scheper RJ, Sonneveld P, Wiemer EA. The vault complex. Cell Mol Life Sci 2003; 60:1828-37; PMID:14523546.
44. Lee K, Kunkeaw N, Jeon SH, Lee I, Johnson BH, Kang GY, et al. Precursor miR-886, a novel noncoding RNA repressed in cancer, associates with PKR and modulates its activity. RNA 2011; 17:1076-89; PMID:21518807; http://dx.doi.org/10.1261/rna.2701111.
45. Berezikov E, Chung WJ, Willis J, Cuppen E, Lai EC. Mammalian mirtron genes. Mol Cell 2007; 28:328-36; PMID:17964270.
46. Okamura K, Chung WJ, Ruby JG, Guo H, Bartel DP, Lai EC. The Drosophila hairpin RNA pathway generates endogenous short interfering RNAs. Nature 2008; 453:803-6; PMID:18463630; http://dx.doi.org/10.1038/nature07015.
47. Ruby JG, Jan CH, Bartel DP. Intronic microRNA precursors that bypass Drosha processing. Nature 2007; 448:83-6; PMID:17589500.
48. Pillai MM, Yang X, Balakrishnan I, Bemis L, Torok-Storb B. MiR-886-3p down regulates CXCL12 (SDF1) expression in human marrow stromal cells. PLoS One 2010; 5:e14304; PMID:21179442; http://dx.doi.org/10.1371/journal.pone.0014304.
49. Asaoka T, Sotolongo B, Island ER, Tryphonopoulos P, Selvaggi G, Moon J, et al. MicroRNA Signature of Intestinal Acute Cellular Rejection in Formalin-Fixed Paraffin-Embedded Mucosal Biopsies. Am J Transplant 2012; 12:458-68; PMID:22026534; http://dx.doi.org/10.1111/j.1600-6143.2011.03807.x.
50. Li JH, Xiao X, Zhang YN, Wang YM, Feng LM, Wu YM, et al. MicroRNA miR-886-5p inhibits apoptosis by down-regulating Bax expression in human cervical carcinoma cells. Gynecol Oncol 2010; 120:145-51; PMID:20947150; http://dx.doi.org/10.1016/j.ygyno.2010.09.009.
51. Xiong Y, Zhang L, Holloway AK, Wu X, Su L, Kebebew E. MiR-886-3p regulates cell proliferation and migration, and is dysregulated in familial nonmedullary thyroid cancer. PLoS One 2011; 6:e24717; PMID:21998631; http://dx.doi.org/10.1371/journal.pone.0024717.
52. Banez-Coronel M, Porta S, Kagerbauer B, Mateu-Huertas E, Pantano L, Ferrer I, et al. A pathogenic mechanism in Huntington's disease involves small CAG-repeated RNAs with neurotoxic activity. PLoS Genet 2012; 8:e1002481; PMID:22383888; http://dx.doi.org/10.1371/journal.pgen.1002481.
53. Dexter DT, Sian J, Rose S, Hindmarsh JG, Mann VM, Cooper JM, et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 1994; 35:38-44; PMID:8285590.
54. Ferrer I. Early involvement of the cerebral cortex in Parkinson's disease: convergence of multiple metabolic defects. Prog Neurobiol 2009; 88:89-103; PMID:19482226; http://dx.doi.org/10.1016/j.pneurobio.2009.02.004.
55. Ferrer I, Martinez A, Blanco R, Dalfo E, Carmona M. Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. J Neural Transm 2011; 118:821-39; PMID:20862500; http://dx.doi.org/10.1007/s00702-010-0482-8.
56. Parker WD Jr., Parks JK, Swerdlow RH. Complex I deficiency in Parkinson's disease frontal cortex. Brain Res 2008; 1189:215-8; PMID:18061150.
57. Schulz-Schaeffer WJ. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol 2010; 120:131-43; PMID:20563819; http://dx.doi.org/10.1007/s00401-010-0711-0.
58. Tanji K, Mori F, Mimura J, Itoh K, Kakita A, Takahashi H, et al. Proteinase K-resistant alpha-synuclein is deposited in presynapses in human Lewy body disease and A53T alpha-synuclein transgenic mice. Acta Neuropathol 2010; 120:145-54; PMID:20339856; http://dx.doi.org/10.1007/s00401-010-0676-z.
59. Mrazek J, Kreutmayer SB, Grasser FA, Polacek N, Huttenhofer A. Subtractive hybridization identifies novel differentially expressed ncRNA species in EBVinfected human B cells. Nucleic Acids Res 2007; 35:e73; PMID:17478510.
60. Obernosterer G, Leuschner PJ, Alenius M, Martinez J. Post-transcriptional regulation of microRNA expression. RNA 2006; 12:1161-7; PMID:16738409.
61. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010; 11:597-610; PMID:20661255; http://dx.doi.org/10.1038/nrg2843.
62. Bohnen NI, Koeppe RA, Minoshima S, Giordani B, Albin RL, Frey KA, et al. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J Nucl Med 2011; 52:848-55; PMID:21571793; http://dx.doi.org/10.2967/jnumed.111.089946.
63. Bohnen NI, Minoshima S, Giordani B, Frey KA, Kuhl DE. Motor correlates of occipital glucose hypometabolism in Parkinson's disease without dementia. Neurology 1999; 52:541-6; PMID:10025784.
64. Eberling JL, Richardson BC, Reed BR, Wolfe N, Jagust WJ. Cortical glucose metabolism in Parkinson's disease without dementia. Neurobiol Aging 1994; 15:329-35; PMID:7936057.
65. Otsuka M, Ichiya Y, Kuwabara Y, Hosokawa S, Sasaki M, Yoshida T, et al. Glucose metabolism in the cortical and subcortical brain structures in multiple system atrophy and Parkinson's disease: A positron emission tomographic study. J Neurol Sci 1996; 144:77-83; PMID:8994107.
66. Beitzinger M, Peters L, Zhu JY, Kremmer E, Meister G. Identification of human microRNA targets from isolated argonaute protein complexes. RNA Biol 2007; 4:76-84; PMID:17637574.
67. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402-8; PMID:11846609.
68. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002; 30:e36; PMID:11972351.
69. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98:5116-21; PMID:11309499.
70. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995; 57:289-300.
71. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5:R80; PMID:15461798.
72. Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 2011; 39:D152-7; PMID:21037258; http://dx.doi.org/10.1093/nar/gkq1027.